Abstract: Disclosed herein are anti-TIM-3 antibodies and antigen-binding fragments, polynucleotides encoding the antibodies and antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and antigen-binding fragments. Uses of the anti-TIM-3 antibodies and antigen-binding fragments described herein in cancer treatment are also disclosed.

Abstract: Disclosed herein are anti-PD-L1 antibodies and antigen-binding fragments thereof, fusion proteins comprising a first domain comprising an anti-PD-L1 antibodies or an antigen-binding fragment thereof and a second domain comprising a fragment of TGF?RII that binds TGF? or a variant thereof, as well as polynucleotides that encode such antibodies or fusion proteins. Disclosed herein are also their uses in treatment of diseases such as cancers.

Abstract: A method and system to determine relatedness select a first customer observable from a first source document, the first customer observable being made up of two terms, the two terms being a first term of a first type and a first term of a second type, and select a second customer observable from a second source document, the second customer observable being made up of a second term of the first type and a second term of the second type. The method includes creating a first corpus of all documents that include the first terms, creating a second corpus of all documents that include the second terms, obtaining other first terms in the first corpus and other second in the second corpus, and performing semantic similarity analysis to determine a similarity score between the first customer observable and the second customer observable.

Abstract: A method and system to determine relatedness select a first customer observable from a first source document, the first customer observable being made up of two terms, the two terms being a first term of a first type and a first term of a second type, and select a second customer observable from a second source document, the second customer observable being made up of a second term of the first type and a second term of the second type. The method includes creating a first corpus of all documents that include the first terms, creating a second corpus of all documents that include the second terms, obtaining other first terms in the first corpus and other second in the second corpus, and performing semantic similarity analysis to determine a similarity score between the first customer observable and the second customer observable.

Abstract: Fusion proteins comprising a transferrin moiety and integrin binding domain and peptide libraries thereof are disclosed. The present invention includes a method of screening transferrin and integrin peptide libraries displayed in fusion proteins expressed by host cells. The fusion proteins of the present invention include transferrin fusion proteins capable of expression in yeast.

Abstract: The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the invention.

Abstract: Fusion proteins comprising a transferrin moiety and integrin binding domain and peptide libraries thereof are disclosed. The present invention includes a method of screening transferrin and integrin peptide libraries displayed in fusion proteins expressed by host cells. The fusion proteins of the present invention include transferrin fusion proteins capable of expression in yeast.

Abstract: Fusion proteins comprising a transferrin moiety, a stalk moiety, and cell wall linking member and peptide libraries thereof are disclosed. The present invention includes a method of screening peptide libraries displayed in fusion proteins expressed by host cells. The fusion proteins of the present invention include transferrin fusion proteins capable of expression in yeast.

Abstract: The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the invention.

Abstract: The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the invention.

Abstract: The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the invention.